ABRYSVO Pfizer Australia Pty Ltd
Product name
ABRYSVO
Sponsor
Accepted date
May-2023
Active ingredients
recombinant respiratory syncytial virus pre-fusion F protein, water for injections
Proposed indication
For the prevention of respiratory tract disease.
Application type
A (new medicine)
Publication date
May-23